3. Liver Diseases

3. Liver Diseases

Based on the fact that chronic hepatitis leads to compensatory hyperplasia of hepatic fibrous tissue, people have also tried using blood-activating and stasis-removing therapy to treat chronic hepatitis, with varying degrees of efficacy. The First Infectious Disease Hospital in Beijing mainly used blood-activating and stasis-removing therapy to treat 8 cases of severe hepatitis, with a mortality rate of only 37.5%. Another 8 patients with roughly the same severity were treated with a combination of traditional Chinese and Western medicine as a control group, resulting in a mortality rate of 83.3%. This demonstrates that blood-activating and stasis-removing therapy has unique advantages in treating severe hepatitis. The Shanghai Infectious Disease Hospital formulated the Tong Qu De Yu Decoction, composed of Tao Ren, Hong Hua, Mu Xiang, Jin Qian Cao, Da Huang, Yuan Ming Fen, and Chuan Pu, to treat jaundice-type infectious hepatitis, achieving satisfactory results. The rapid improvement of symptoms and the swift recovery of liver function are difficult to match with ordinary liver-protective therapies. In the Shanghai area, Shi Xiao San, Xia Yu Xue Tang, and Ping Di Mu were also used to treat protracted and chronic hepatitis, while Dang Gui, San Leng, E Zhu, and Bie Jia Jian Wan were used to treat splenomegaly and cirrhotic ascites caused by various reasons, totaling over 200 cases, all of which also achieved good therapeutic effects. The Zhongshan Hospital of the First Shanghai Medical College used the basic blood-activating and stasis-removing formula (Da Huang, Tao Ren, Tu Bie Chong, Dang Gui, Chi Shao, Yuan Ming Fen, Dan Shen) to treat 18 cases of protracted and chronic hepatitis and 18 cases of early-stage cirrhosis, with symptom improvement observed in 70%–80% of cases and liver shrinkage in one-third of cases.